Table S7.
DHEA Modulation of Vaccine Efficacy
| Dosage | Timing (before/after vaccination) | Control | Population | Vaccine Type | Outcome | Citation | |
|---|---|---|---|---|---|---|---|
| DHEA | 50 mg BID DHEAS (oral) 100mg total daily dosage | 4 days, starting 2 days prior to vaccination | 50 mg corn starch BID Total daily dose 100mg | Males 65+ years n=66 |
Tetanus booster | No significant change in vaccine responsea | Araneo et al63 |
| DHEA | 50 mg BID DHEA (oral) 100mg total daily dosage | 4 days, starting 2 days prior to vaccination | Not specified | 61-89 years n=71 |
TIV | No significant change in vaccine responsea Possible negative effect on vaccine response in individuals without baseline protective antibody titers. | Danenberg et al64 |
| DHEA | 7.5 mg subcutaneous DHEAS | Single dose concurrent to vaccination | Vaccination only | 73-90 years n=78 Control group consisted of adults <40 years |
TIV | Significantly improved serological protection for H3N2 in those with low pre-vaccination titers and lower DHEAS levels, but not other strainsb | Degelau et al65 |
aNo significant effect on/association with vaccine response
bSignificant effect on/association with vaccine response for at least one vaccine strain/subgroup